{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_6340", "batch_size": 200, "batch_pos": 69, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"hop_idx": 2, "answer": "uncertain", "rationale": "Missing response from batch", "method": "fallback", "batch_id": "batch_2_18740", "batch_size": 200, "batch_pos": 61, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment factually reports on trial plans and response speed without using high-potency verbs, metaphors, superlatives, intensifiers, or alert phrases.", "method": "llm_batch_retry", "retry": 1, "batch_id": "batch_2_18740_r1", "batch_size": 200, "batch_pos": 61, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "'plans to launch' refers to future/plan, not realised impact.", "method": "llm_batch", "batch_id": "batch_3_5684", "batch_size": 200, "batch_pos": 48, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a question.", "method": "llm_batch", "batch_id": "batch_4_16596", "batch_size": 200, "batch_pos": 46, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a question.", "method": "llm_batch", "batch_id": "batch_4_16596", "batch_size": 200, "batch_pos": 46, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"hop_idx": 5, "answer": "uncertain", "rationale": "Missing response from batch", "method": "fallback", "batch_id": "batch_5_13576", "batch_size": 200, "batch_pos": 45, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "This segment discusses future plans and potential response speed but lacks explicit calming language or intensified low-risk statements.", "method": "llm_batch_retry", "retry": 1, "batch_id": "batch_5_13576_r1", "batch_size": 200, "batch_pos": 45, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "No minimiser + scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_5836", "batch_size": 200, "batch_pos": 29, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_20524", "batch_size": 200, "batch_pos": 27, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes plan for human trial and ability to respond quickly ('plans to launch a small human trial', 'could respond very quickly') without active reassurance.", "method": "llm_batch", "batch_id": "batch_8_21104", "batch_size": 200, "batch_pos": 144, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
